NCT05628441 is a clinical trial of Computer Aided Detection system for Barrett's neoplasia in Barrett Esophagus, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Who is sponsoring NCT05628441?

NCT05628441 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

What drugs are being tested in NCT05628441?

Interventions in NCT05628441: Computer Aided Detection system for Barrett's neoplasia.

What condition does NCT05628441 study?

NCT05628441 studies Barrett Esophagus, Barrett Adenocarcinoma.

Is NCT05628441 still recruiting?

NCT05628441 is currently completed. Last updated 28 November 2022.

Last reviewed 2022-11-28 · How we verify

NCT05628441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-time Computer Aided Detection of Barrett's Neoplasia

Completed Last updated 28 November 2022

What this trial tests

trial testing Computer Aided Detection system for Barrett's neoplasia in Barrett Esophagus in 30 participants. Completed in 13 October 2022.

Timeline

16 May 2022

Primary endpoint
13 October 2022

13 October 2022

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	16 May 2022
Primary completion	13 October 2022
Estimated completion	13 October 2022
Sites	1 location across Netherlands

Drugs / interventions tested

Computer Aided Detection system for Barrett's neoplasia

Conditions studied

Barrett Esophagus — all drugs for Barrett Esophagus →
Barrett Adenocarcinoma — all drugs for Barrett Adenocarcinoma →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

Adults 18 to 99, any sex, with Barrett Esophagus or Barrett Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the real-time pilot study, the performance of a recently developed Computer Aided Detection (CADe) system will be investigated in 30 patients during real-time live endoscopic examination. Three expert endoscopists in the field of Barrett's esophagus and endoscopic resection techniques will perform the inclusions following a standardized data acquisition protocol. In total, 15 patients with a visible neoplastic lesion in their Barrett's esophagus and 15 patients without any visible abnormalities in their Barrett's esophagus will be included in this study. Outcomes: to investigate feasibility of the use of the CADe system in the endoscopy suite, to investigate the performance of the CADe system when used by endoscopists.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The use of a real-time computer-aided detection system for visible lesions in the Barrett's esophagus during live endoscopic procedures: a pilot study (with video).
Fockens KN, Jukema JB, Jong MR, Boers T, et al · · 2024 · cited 8× · PMID 38604297 · DOI 10.1016/j.gie.2024.04.011

Verify or expand the search:

Other recruiting trials for Barrett Esophagus

Currently open trials in the same condition.

NCT07126535 — Impact of RFA on Esophageal Distensibility and Mucosal Impedance · recruiting
NCT06746623 — Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux · NA · recruiting
NCT06687603 — Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms · NA · recruiting
NCT06803147 — "Less-is-more in Barrett-surveillance" Care Evaluation of Barrett's Patients With Low-Risk in Whom Endoscopic Surveillan · recruiting
NCT06693622 — Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests · recruiting

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

NCT07301021 — Velopharyngeal Insufficiency After Maxillomandibular Advancement Osteotomy in Obstructive Sleep Apnea Patients · not yet recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT07457957 — Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents · NA · not yet recruiting
NCT06909045 — Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease · NA · recruiting
NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05628441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last refreshed: 28 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05628441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing